Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain

Pain

Volumn 69, Issue 3, 1997, Pages 295-302

  Gourlay, Geoffrey K ^a   Cherry, David A ^a   Onley, Margaret M ^a   Tordoff, Simon G ^a   Conn, David A ^a   Hood, Gillian M ^a   Plummer, John L ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Kadian ; Kapanol ; Morphine metabolites; Morphine pharmacodynamics; Morphine pharmacokinetics; MS Contin ; Sustained release morphine pharmacodynamics; Sustained release morphine pharmacokinetics

Indexed keywords

DEXTROMORAMIDE; MORPHINE; MORPHINE SULFATE;

ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; TREATMENT OUTCOME;

EID: 0031018992     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(96)03269-1     Document Type: Article

References (9)

1. Gourlay, G.K., Cherry, D.A. and Cousins, M.J., A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 25 (1986) 297-312.
2. Gourlay, G.K., Cousins, M.J. and Cherry, D.A., Drug therapy. In: G.D. Burrows, D. Elton, and G.V. Stanley (Eds.), Handbook of Chronic Pain Management, Elsevier, Amsterdam, 1987, pp. 163-192.
3. Gourlay, G.K., Plummer, J.L., Cherry, D.A. and Onley, M.M., A comparison of Kapanol (a new sustained release morphine formulation), MST Continus, and morphine solution in cancer patients: pharmacokinetic aspects of morphine and morphine metabolites. In: G.F. Gebhart, D.L. Hammond and T.S. Jensen (Eds.), Progress in Pain Research and Management, Vol. 2, IASP Press, Seattle, 1994, pp. 631-643.
4. Hull, C.J., Pharmacokinetics for Anaesthesia, Butterworth Heinemann, Oxford, 1991, pp. 168-169.
5. Milne, R.W., Nation, R.L., Reynolds, G.D., Somogyi, A.A. and Van Crugten, J.T., High performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies, J. Chromatogr., 565 (1991) 457-464.
6. Schug, S.A., Zech, D., Grond, S., Jung, H., Meuser, T. and Stobbe. B., A long term survey of morphine in cancer pain patients, J. Pain Symptom Manage., 7 (1992) 259-266.
7. Todd, R.D., Muldoon, S.M. and Watson, R.L., Determination of morphine in cerebrospinal fluid and plasma by high-performance liquid chromatography with electrochemical detection, J. Chromatog., 232 (1982) 101-110.
8. Walker, V.A., Hoskin, P.J., Hanks, G.W. and White, I.D., Evaluation of WHO analgesic guidelines for cancer pain in a hospital based palliative care unit, J. Pain Symptom Manage., 3 (1988) 145-149.
9. WHO Cancer Pain Relief, WHO, Geneva, 1986.